Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 7, 2007, Pages 2373-2377

  Miró, José M ^a,b   García de la Mària, Cristina ^a   Armero, Yolanda ^a   De Lazzari, Elisa ^a   Soy, Dolors ^a   Moreno, Asunción ^a   Del Rio, Ana ^a   Almela, Manel ^a   Mestres, Carlos A ^a   Gatell, José M ^a   Jiménez de Anta, María Teresa ^a   Marco, Francesc ^a   Miro J M ^c   Moreno, A ^c   Del Rio, A ^c   Gatell, J M ^c   Marco, F ^d   Garcia De La Maria C ^d   Armero, Y ^d   Almela, M ^d   Jimenez De Anta M T ^d   Mestres, C A ^e   Cartana R ^e   Ninot, S ^e   Pomar, J L ^e   Azqueta, M ^e   Sitges, M ^e   Pare J C ^e   Sanz, G ^e   Perez, N ^f   Ramirez J ^f   Ribalta, T ^f   Brunet, M ^g   Soy, D ^h   De Lazzari, E ⁱ   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Infectious Diseases Service   (Spain)

^d Microbiology Service   (Spain)

^e Cardiovascular Institute

^f Pathology Department   (Spain)

^g Toxicology Service   (Spain)

^h Pharmacy Service   (Spain)

ⁱ Epidemiology and Statistics Unit

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPEPTIDE; TELAVANCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL ENDOCARDITIS; COLONY FORMING UNIT; COMPUTER SYSTEM; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; EXPERIMENTAL INFECTION; INFUSION PUMP; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; SIMULATION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

AMINOGLYCOSIDES; ANIMALS; ANTI-INFECTIVE AGENTS; AORTIC VALVE; COLONY COUNT, MICROBIAL; ENDOCARDITIS, BACTERIAL; HEART VALVE DISEASES; HUMANS; INFUSION PUMPS; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; MODELS, THEORETICAL; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 34447285213     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01266-06     Document Type: Article

References (43)

1. Appelbaum, P. C. 2006. MRSA - the tip of the iceberg. Clin. Microbiol. Infect. 12(Suppl. 2):3-10.
2. Baddour, L. M., W. R. Wilson, A. S. Bayer, V. G. Fowler, Jr., A. F. Bolger, M. E. Levison, P. Ferrieri, M. A. Gerber, L. Y. Tani, M. H. Gewitz, D. C. Tong, J. M. Steckelberg, R. S. Baltimore, S. T. Shulman, J. C. Burns, D. A. Falace, J. W. Newburger, T. J. Pallasch, M. Takahashi, and K. A. Taubert. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111:e394-e434.
3. Bayés, M., X. Rabasseda, and J. R. Prous. 2005. Gateways to clinical trials: April 2005. Methods Find. Exp. Clin. Pharmacol. 27:193-219.
4. Blouin, R. A., L. A. Bauer, D. D. Miller, K. E. Record, and W. O. Griffin, Jr. 1982. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob. Agents Chemother. 21:575-580.
5. Cabell, C. H., J. G. Jollis, G. E. Peterson, G. R. Corey, D. J. Anderson, D. J. Sexton, C. W. Woods, L. B. Reller, T. Ryan, and V. G. Fowler, Jr. 2002. Changing patient characteristics and the effect on mortality in endocarditis. Arch. Intern. Med. 162:90-94.
6. Chang, S., D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover, F. P. Downes, S. Shah, J. T. Rudrik, G. R. Pupp, W. J. Brown, D. Cardo, and S. K. Fridkin for the Vancomycin-Resistant Staphylococcus aureus Investigative Team. 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:1342-1347.
7. Cremieux, A. C., B. Maziere, J. M. Vallois, M. Ottaviani, A. Azancot, H. Raffoul, A. Bouvet, J. J. Pocidalo, and C. Carbon. 1989. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J. Infect. Dis. 159:938-944.
8. Eliopoulos, G., and R. Moellering. 1996. Antimicrobial combinations, p. 330-396. In V. Lorian (ed.), Antibiotics in laboratory medicine, 5th ed. Williams & Wilkins, Baltimore, MD.
9. Ellis, M. W., and J. S. Lewis II. 2005. Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr. Opin. Infect. Dis. 18:496-501.
10. Fowler, V. G., Jr., J. M. Miró, B. Hoen, C. H. Cabell, E. Abrutyn, E. Rubinstein, G. R. Corey, D. Spelman, S. F. Bradley, B. Barsic, P. A. Pappas, K. J. Anstrom, D. Wray, C. Q. Fortes, I. Anguera, E. Athan, P. Jones, J. T. M. van der Meer, T. S. J. Elliott, D. P. Levine, and A. S. Bayer for the ICE Investigators. 2005. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293:3012-3021.
11. Fowler, V. G., Jr., H. W. Boucher, G. R. Corey, E. Abrutyn, A. W. Karchmer, M. E. Rupp, D. P. Levine, H. F. Chambers, F. P. Tally, G. A. Vigliani, C. H. Cabell, A. S. Link, I. DeMeyer, S. G. Filler, M. Zervos, P. Cook, J. Parsonnet, J. M. Bernstein, C. S. Prince, G. N. Forrest, G. Fätkenheuer, M. Gareca, S. J. Rehm, H. R. Brodt, A. Tice, and S. E. Cosgrove for the S. aureus Endocarditis and Bacteremia Study Group. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
12. Gander, S., A. Kinnaird, and R. Finch. 2005. Telavancin: in vitro activity against staphylococci in a biofilm model. J. Antimicrob. Chemother. 56:337-343.
13. Garrison, P. K., and L. R. Freedman. 1970. Experimental endocarditis. I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in right side of the heart. Yale J. Biol. Med. 42:394-410.
14. Gavaldà, J., P. J. Cardona, B. Almirante, J. A. Capdevila, M. Laguarda, L. Pou, E. Crespo, C. Pigrau, and A. Pahissa. 1996. Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum. Antimicrob. Agents Chemother. 40:173-178.
15. Goldstein, E. J. C., D. M. Citron, C. V. Merriam, Y. A. Warren, K. L. Tyrrell, and H. T. Fernandez. 2004. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob. Agents Chemother. 48:2149-2152.
16. Hegde, S. S., N. Reyes, T. Wiens, N. Vanasse, R. Skinner, J. McCullough, K. Kaniga, J. Pace, R. Thomas, J.-P. Shaw, G. Obedencio, and J. K. Judice. 2004. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob. Agents Chemother. 48:3043-3050.
17. Higgins, D. L., R. Chang, D. V. Debabov, J. Leung, T. Wu, K. M. Krause, E. Sandvik, J. M. Hubbard, K. Kaniga, D. E. Schmidt, Jr., Q. Gao, R. T. Cass, D. E. Karr, B. M. Benton, and P. P. Humphrey. 2005. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:1127-1134.
18. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
19. Kanafani, Z. A., and V. G. Fowler, Jr. 2006. Staphylococcus aureus infections: new challenges from an old pathogen. Enferm. Infecc. Microbiol. Clin. 24:182-193.
20. King, A., I. Phillips, and K. Kaniga. 2004. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J. Antimicrob. Chemother. 53:797-803.
21. Madrigal, A. G., L. Basuino, and H. F. Chambers. 2005. Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3163-3165.
22. Maltezou, H. C., and H. Giamarellou. 2006. Community-acquired methicillin-resistant Staphylococcus aureus infections. Int. J. Antimicrob. Agents 27:87-96.
23. Miró, J. M., I. Anguera, C. H. Cabell, A. Y. Chen, J. A. Stafford, G. R. Corey, L. Olaison, S. Eykyn, B. Hoen, E. Abrutyn, D. Raoult, A. Bayer, V. G. Fowler, Jr., and the International Collaboration on Endocarditis Merged Database Study Group. 2005. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin. Infect. Dis. 41:507-514.
24. Miró, J. M., F. Marco, C. García de la Mària, Y. Armero, E. Amat, D. Soy, A. Moreno, A. del Rio, M. Almela, C. A. Mestres, J. Gatell, and M. T. Jímenez de Anta. 2006. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediately susceptible Staphylococcus aureus (GISA). Clin. Microbiol. Infect. 12(Suppl. 4):1158.
25. Naimi, T. S., K. H. LeDell, K. Como-Sabetti, S. M. Borchardt, D. J. Boxrud, J. Etienne, S. K. Johnson, F. Vandenesch, S. Fridkin, C. O'Boyle, R. N. Danila, and R. Lynfield. 2003. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290:2976-2984.
26. National Committee for Clinical Laboratory Standards. 2001. Performance standards for antimicrobial susceptibility testing. 9th informational supplement. Document M100-S11, vol. 21, no. 1. National Committee for Clinical Laboratory Standards, Villanova, PA.
27. Pace, J. L., and J. K. Judice. 2005. Telavancin (Theravance). Curr. Opin. Investig. Drugs 6:216-225.
28. Pace, J. L., K. Krause, D. Johnston, D. Debabov, T. Wu, L. Farrington, C. Lane, D. L. Higgins, B. Christensen, J. K. Judice, and K. Kaniga. 2003. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:3602-3604.
29. Pfeltz, R. F., and B. J. Wilkinson. 2004. The escalating challenge of vancomycin resistance in Staphylococcus aureus. Curr. Drug Targets Infect. Disord. 4:273-294.
30. Reyes, N., R. Skinner, B. M. Benton, K. M. Krause, J. Shelton, G. P. Obedencio, and S. S. Hegde. 2006. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58:462-465.
31. Reyes, N., R. Skinner, K. Kaniga, K. M. Krause, J. Shelton, G. P. Obedencio, A. Gough, M. Conner, and S. S. Hegde. 2005. Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:4344-4346.
32. Ruef, C. 2004. Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus. Infection 32:315-327.
33. Sakoulas, G., G. Eliopoulos, J. Alder, and C. Thauvin-Eliopoulos. 2003. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47:1714-1718.
34. Schmidt-Ioanas, M., A. de Roux, and H. Lode. 2005. New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient. Curr. Opin. Crit. Care 11:481-486.
35. Shaw, J. P., J. Seroogy, K. Kaniga, D. L. Higgins, M. Kitt, and S. Barriere. 2005. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49:195-201.
36. Sievert, D. M., M. L. Boulton, G. Stoltman, D. Johnson, M. G. Stobierski, F. P. Downes, P. A. Somsel, J. T. Rudrik, W. Brown, W. Hafeez, T. Lundstrom, E. Flanagan, R. Johnson, J. Mitchell, and S. Chang. 2002. Staphylococcus aureus resistant to vancomycin - United States, 2002. Morb. Mortal. Wkly. Rep. 51:565-567.
37. Small, P. M., and H. F. Chambers. 1990. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother. 34:1227-1231.
38. Smith, T. L., M. L. Pearson, K. R. Wilcox, C. Cruz, M. V. Lancaster, B. Robinson-Dunn, F. C. Tenover, M. J. Zervos, J. D. Band, E. White, and W. R. Jarvis for the Glycopeptide-intermediate Staphylococcus aureus Working Group. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med. 340:493-501.
39. Stryjewski, M. E., V. H. Chu, W. D. O'Riordan, B. L. Warren, L. M. Dunbar, D. M. Young, M. Vallée, V. G. Fowler, Jr., J. Morganroth, S. L. Barriere, M. M. Kitt, and G. R. Corey for the FAST 2 Investigator Group. 2006. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob. Agents Chemother. 50:862-867.
40. Stryjewski, M. E., W. D. O'Riordan, W. K. Lau, F. D. Pien, L. M. Dunbar, M. Vallee, V. G. Fowler, Jr., V. H. Chu, E. Spencer, S. L. Barriere, M. M. Kitt, C. H. Cabell, and G. R. Corey for the FAST Investigator Group. 2005. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin. Infect. Dis. 40:1601-1607.
41. Stucki, A., P. Gerber, F. Acosta, M. Cottagnoud, and P. Cottagnoud. 2006. Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters. Antimicrob. Agents Chemother. 50:770-773.
42. Sun, H. K., K. Duchin, C. H. Nightingale, J.-P. Shaw, J. Seroogy, and D. P. Nicolau. 2006. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob. Agents Chemother. 50:788-790.
43. Wootton, M., R. A. Howe, T. R. Walsh, P. M. Bennett, and A. P. MacGowan. 2002. In vitro activity of 21 antimicrobials against vancomycin-resistant Staphylococcus aureus (VRSA) and heteroVRSA (hVRSA). J. Antimicrob. Chemother. 50:760-761.